Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

79.25 +1.58 (+2.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,464,010
Open 77.20
Bid (Size) 78.19 (4)
Ask (Size) 79.50 (1)
Prev. Close 77.67
Today's Range 76.92 - 79.29
52wk Range 61.91 - 84.86
Shares Outstanding 221,505,011
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
7 Defensive Stocks to Buy for a Bear Market
As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market. 
Via InvestorPlace

Performance

YTD
+7.14%
+7.14%
1 Month
+7.25%
+7.25%
3 Month
-2.05%
-2.05%
6 Month
+7.14%
+7.14%
1 Year
-4.91%
-4.91%

More News

Read More
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
Via Benzinga
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
Via Benzinga
4 Analysts Have This to Say About Incyte
Via Benzinga
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
Via Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
Via Benzinga
Insights On Incyte Corporation
Via Talk Markets
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
Incyte: Q1 Earnings Insights
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
Via Investor's Business Daily
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
Via Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Via Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
Via Investor's Business Daily
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.